Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis-Reference-Cited by-同舟云学术

Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis

Published:2016-08-01 Issue:23 Volume:122 Page:3650-3656
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Sasaki Koji¹²,Jabbour Elias J.¹,Ravandi Farhad¹,Short Nicholas J.³,Thomas Deborah A.¹,Garcia-Manero Guillermo¹,Daver Naval G.¹,Kadia Tapan M.¹,Konopleva Marina Y.¹,Jain Nitin¹,Issa Ghayas C.³,Jeanis Vicki¹,Moore Haim G.¹,Garris Rebecca S.¹,Pemmaraju Naveen¹,Cortes Jorge E.¹,O'Brien Susan M.⁴^ORCID,Kantarjian Hagop M.¹

Affiliation:

1. Department of Leukemia; The University of Texas MD Anderson Cancer Center; Houston Texas

2. Department of Hematology; Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University; Tokyo Japan

3. Division of Cancer Medicine; The University of Texas MD Anderson Cancer Center; Houston Texas

4. Clinical Science; Chao Family Comprehensive Cancer Center, University of California at Irvine; Orange California

Funder

The University of Texas MD Anderson Cancer Center

Charif Souki Cancer Research Fund

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.30231/fullpdf

Reference22 articles.

1. UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia;Fielding;Blood.,2014

2. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia;Ravandi;Blood.,2010

3. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031;Schultz;Leukemia.,2014

4. Acute lymphoblastic leukemia, Version 2.2015;Alvarnas;J Natl Compr Canc Netw.,2015

5. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia;Ravandi;Cancer.,2015

Cited by 150 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase 2 trial of induction with dasatinib and consolidation with hyper-CVAD plus dasatinib followed by allografting for Ph-positive acute lymphoblastic leukemia in adults;Leukemia Research;2024-02

2. Diagnostic and therapeutic advances in adults with acute lymphoblastic leukemia in the era of gene analysis and targeted immunotherapy;The Korean Journal of Internal Medicine;2024-01-01

3. ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia;Annals of Oncology;2024-01

4. Ponatinib Improved the Prognosis of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Japanese Single-Center Cohort Study;Cureus;2023-12-12

5. How to Manage Philadelphia-Positive Acute Lymphoblastic Leukemia in Resource-Constrained Settings;Cancers;2023-12-10